- Rodman & Renshaw says it executed over US$4B in 2025 capital-raising across public and private markets as it nears its 75th anniversary.
- The firm is strengthening healthcare and research leadership with Michael King as Director of Research and Gavin Samuels as Investment Banking Managing Director.
- It is promoting StockBlock, an electronic ECM platform designed to improve issuance transparency, speed, and direct issuer-to-institution connectivity.
- Deal disclosures show steady lower-middle-market activity across ATMs, registered directs, and placements, including a cited US$1B ATM in 2025.
Read More
The press release presents Rodman & Renshaw as exhibiting a strong performance trajectory into their 75th year, leaning into both institutional strength and technology-driven differentiation. Their claimed US$4 billion in capital raised demonstrates capability, but public records (including transaction tombstones) suggest that while they have led or placed many sizeable ATMs and other offerings, aggregating to large sums, the dispersion across many deals (often tens or low hundreds of millions) means verification of the full US$4 billion number will need granular auditing.
The dual leadership appointments indicate a focus on deepening healthcare/life sciences expertise (via Samuels) and reinstating experienced research leadership (via King). This suggests an emphasis on sectors with growth promise—particularly life sciences—and on the research-driven deal origination model. However, the challenges here include competition in healthcare advisory and ensuring research commentary translates into transaction pipeline.
The StockBlock platform strategy is perhaps the most strategically differentiated element. As Rodman describes, StockBlock functions as an eECM platform enabling issuers direct visibility into institutional demand, live management interactions, and more control over execution. In a market where speed, transparency, and certainty are increasingly prized, this could offer competitive advantage vs. traditional underwriting or brokerage-led issuance. Potential risks include regulatory, execution risk, liquidity of block trades on non-standard platforms, and client adoption curve.
Reviewing their transaction history (via their website), Rodman & Renshaw appear to have maintained consistent deal flow across ATMs, registered directs, private placements, warrants etc. Notably, they were lead or agent on a US$1 billion ATM in September 2025, several US$75–100 million ATMs and other offering types regularly. These major deals underpin the narrative of momentum.
Strategic implications: If Rodman & Renshaw can leverage their StockBlock platform effectively, they may position themselves as a leader in digital capital markets solutions for growth companies, especially in healthcare and middle-market sectors. It also signals that they may challenge more traditional ECM investment banks. Key open questions: how much of 2025’s activity was due to favorable market conditions vs. differentiated execution; whether the StockBlock platform is scaling; whether healthcare hires translate into deal wins; risk around dilution, regulation, and platform acceptance.
Supporting Notes
- “Executed over $4 billion in capital-raising transactions … across public and private markets” is the headline 2025 performance claimed by Rodman & Renshaw.
- Michael King named Director of Research, bringing “more than two decades of experience … including Head of Research at Rodman & Renshaw from 2005 to 2009”.
- Gavin Samuels appointed as Managing Director, Investment Banking, with senior roles at Merck, Pfizer, Teva Pharmaceuticals, focusing on healthcare and life sciences transactions.
- Rodman’s continued strategic collaboration with StockBlock, described as “a next-generation electronic Equity Capital Markets platform … to enhance deal execution and efficiency”; and from their website, description of StockBlock enabling issuers to transact on their terms, with transparency and direct access to institutional investors.
- From their transaction history: in September 2025, Rodman & Renshaw led a US$1 billion At-The-Market Offering; additional large ATM and registered direct offerings in late 2025 (e.g. US$75 million, US$100 million ATMs).
- Rodman & Renshaw’s “Capabilities” section confirms they handle a range of capital markets tools (ATMs, Registered Directs, Bought Deals, etc.) and have executed over 500 transactions in past 25 years, ranking among top banks by number of deals in middle‐market segment.
Sources
- Rodman & Renshaw press release: “Rodman & Renshaw Marks 75th Anniversary …” on EIN Presswire (January 9, 2026) — performance, leadership, StockBlock details.
- Rodman & Renshaw website — StockBlock description and features.
- Rodman & Renshaw website — investment banking & transactions pages showing recent tombstones and deal sizes.